Cost-utility analysis of the treatment of relapsing-remitting multiple sclerosis with glatiramer acetate or interferon beta in Spain

被引：0
|
作者：
Rubio-Terrés, C
Medina, F
Aristegui, I
Izquierdo, G
机构：
[1] Aventis Pharma SA, Madrid, Spain
[2] Hosp Univ Virgen Macarena, Seville, Spain
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)64043-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：277 / 277
页数：1
相关论文
共 50 条
  • [1] Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain
    Rubio-Terrés, C
    Hurlé, ADG
    REVISTA DE NEUROLOGIA, 2005, 40 (12) : 705 - 710
  • [2] Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis
    Oreja-Guevara, C.
    Bermejo, P. E.
    Miralles, A.
    Gabaldon, L.
    Aguilar, M. J.
    Diez-Tejedor, E.
    NEUROLOGIA, 2009, 24 (07): : 435 - 438
  • [3] COST ANALYSIS OF GLATIRAMER ACETATE VERSUS FINGOLIMOD FOR THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Sanchez-de la Rosa, R.
    Sabater, E.
    Casado, M. A.
    VALUE IN HEALTH, 2012, 15 (07) : A551 - A551
  • [4] Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Johnson, Kenneth P.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 371 - 384
  • [5] COST ANALYSIS OF THE USE OF GLATIRAMER ACETATE COMPARED TO INTERFERON-A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS AND SPASTICITY IN SPAIN
    Sanchez de la Rosa, R.
    Garcia Bujalance, L.
    Meca Lallana, J.
    VALUE IN HEALTH, 2014, 17 (07) : A394 - A394
  • [6] Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria
    Walter, Evelyn
    Berger, Thomas
    Bajer-Kornek, Barbara
    Deisenhammer, Florian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (03) : 226 - 237
  • [7] Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
    Sanchez-de la Rosa R.
    Sabater E.
    Casado M.A.
    Health Economics Review, 3 (1) : 1 - 5
  • [8] Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis
    Kalincik, Tomas
    Jokubaitis, Vilija
    Izquierdo, Guillermo
    Duquette, Pierre
    Girard, Marc
    Grammond, Pierre
    Lugaresi, Alessandra
    Oreja-Guevara, Celia
    Bergamaschi, Roberto
    Hupperts, Raymond
    Grand'Maison, Francois
    Pucci, Eugenio
    Van Pesch, Vincent
    Boz, Cavit
    Iuliano, Gerardo
    Fernandez-Bolanos, Ricardo
    Flechter, Shlomo
    Spitaleri, Daniele
    Cristiano, Edgardo
    Verheul, Freek
    Lechner-Scott, Jeannette
    Amato, Maria Pia
    Antonio Cabrera-Gomez, Jose
    Saladino, Maria Laura
    Slee, Mark
    Moore, Fraser
    Gray, Orla
    Paine, Mark
    Barnett, Michael
    Havrdova, Eva
    Horakova, Dana
    Spelman, Timothy
    Trojano, Maria
    Butzkueven, Helmut
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (09) : 1159 - 1171
  • [9] Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
    Stephanie R. Earnshaw
    Jonathan Graham
    MerriKay Oleen-Burkey
    Jane Castelli-Haley
    Kenneth Johnson
    Applied Health Economics and Health Policy, 2009, 7 (2) : 91 - 108
  • [10] Cost Effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis
    Earnshaw, Stephanie
    Graham, Jonathan
    Oleen-Burkey, MerriKay
    Castelli-Haley, Jane
    Johnson, Kenneth
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2009, 7 (02) : 91 - 108
12345